Press "esc" to clear
Go to Advanced Search

Showing results

110 of 765
DaverNaval2.jpg

Article ID: 703788

Immunotherapy combination and chemotherapy show encouraging results in Phase II acute myeloid leukemia study

University of Texas M. D. Anderson Cancer Center

A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called azacitidine, has shown promising results for treatment of relapsed or refractory acute myeloid leukemia (AML), according to findings from a Phase II study at The University of Texas MD Anderson Cancer Center.

Released:
13-Nov-2018 10:05 AM EST
yinghong_wang.jpg
  • Embargo expired:
    12-Nov-2018 11:00 AM EST

Article ID: 703758

Fecal transplant effective against immunotherapy-induced colitis

University of Texas M. D. Anderson Cancer Center

For the first time, transplanting gut bacteria from healthy donors was used to successfully treat patients suffering from severe colitis caused by treatment with immune checkpoint inhibitors. The study from The University of Texas MD Anderson Cancer Center, which includes two patients, suggests fecal microbiota transplantation is worth investigating in clinical trials as a therapy for this common side effect of immunotherapy.

Released:
12-Nov-2018 6:20 AM EST
Cesar-Arias-web.jpg

Article ID: 703719

UTHealth leads race to demystify antibiotic resistance and win the war against superbugs

University of Texas Health Science Center at Houston

Antibiotic resistance is predicted to be the No. 1 cause of death in the world by 2050, but a team of scientists and physicians at The University of Texas Health Science Center at Houston (UTHealth) is determined to help stop this grave prediction from becoming a reality.

Released:
9-Nov-2018 12:05 PM EST

Article ID: 703680

First-ever prostate cancer treatment uses gold nanoparticles to destroy tumorous cells

University of Texas Health Science Center at Houston

A small clinical trial using gold nanoparticles that act as tumor-seeking missiles on a mission to remove prostate cancer has begun at The University of Texas Health Science Center at Houston (UTHealth). It is the first trial of its kind in the world.

Released:
8-Nov-2018 4:05 PM EST
DaverNaval.jpg
  • Embargo expired:
    8-Nov-2018 9:00 AM EST

Article ID: 703502

Combination chemotherapy and immunotherapy effective in Phase II leukemia study

University of Texas M. D. Anderson Cancer Center

A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated an encouraging response rate and overall survival in patients with relapsed or refractory acute myeloid leukemia (AML) according to findings from a Phase II study at The University of Texas MD Anderson Cancer Center.

Released:
7-Nov-2018 9:00 AM EST
  • Embargo expired:
    31-Oct-2018 5:00 PM EDT

Article ID: 703071

Minimally Invasive Surgery Associated with Worse Survival for Women with Cervical Cancer Compared to Open Hysterectomy

University of Texas M. D. Anderson Cancer Center

When comparing standard-of-care surgical options for women with early-stage cervical cancer, two studies led by researchers at The University of Texas MD Anderson Cancer Center discovered that minimally invasive radical hysterectomy is associated with higher recurrence rates and worse overall survival (OS), compared to abdominal radical hysterectomy.

Released:
30-Oct-2018 5:00 PM EDT
SODSPHCulinaryClassHalloweenweb1.jpg

Article ID: 703128

Pioneering Culinary Dentistry Program Enters Halloween Spirit to Offer Fiendishly Healthy Options

University of Texas Health Science Center at Houston

Beheaded stuffed peppers, graveyard chocolate hummus and creepy crawly pumpkin bars were among the Halloween-themed treats created by students at The University of Texas Health Science Center at Houston (UTHealth) School of Dentistry who were learning how to cook as part of a new program in partnership with UTHealth School of Public Health.

Released:
31-Oct-2018 10:30 AM EDT
Hwang_R.jpg
  • Embargo expired:
    24-Oct-2018 2:00 PM EDT

Article ID: 702623

Suppression of DKK3 protein thwarts pancreatic tumor progression and prolongs survival

University of Texas M. D. Anderson Cancer Center

Researchers at The University of Texas MD Anderson Cancer Center have shed new light on why pancreatic tumors are so resistant to therapy.

Released:
23-Oct-2018 2:05 PM EDT

Showing results

110 of 765

Chat now!